Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors

Therapeutic Drug Monitoring

Volumn 21, Issue 1, 1999, Pages 105-115

  Balant Gorgia, Androniki E ^a,b   Gex Fabry, Marianne ^a   Genet, Chantal ^a   Balant, Luc P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b U de Monitoring Therapeutique   (Switzerland)

Author keywords

Age effect; Analytic method; Interindividual variability; Risperidone; Therapeutic drug monitoring

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CHLORPROMAZINE; CITALOPRAM; FLUOXETINE; HYPNOTIC AGENT; LAXATIVE; LITHIUM; NEUROLEPTIC AGENT; PALIPERIDONE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; AGE; AGED; ANALYTIC METHOD; ARTICLE; BODY WEIGHT; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; STEADY STATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; RISPERIDONE; VARIATION (GENETICS);

EID: 0032985205     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199902000-00017     Document Type: Article

References (31)

1. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis. Int Clin Psychopharmacol 1995;10:207-13.
2. Chouinard G, Jones B, Remington G, et al. A canadian multicenter placebo-controlled study of fixed doses of risperidone and halo-peridol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
3. Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994;48:253-73.
4. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
5. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997;17: 194-201.
6. He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 1995;10:19-30.
7. Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: A summary. J Clin Psychiatry 1994;55: 13-7.
8. Byerly MJ, De Vane CL. Pharmacokinetics of clozapine and risperidone: A review of recent literature. J Clin Psychopharmacol 1996;16:177-87.
9. Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993;21:1134-41.
10. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995;122:223-9.
11. Ereshefsky L, Anderson CB, True J, et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy 1993;13:292.
12. Huffman DW, Winer MST, Bartels SJ, et al. Relationships between therapeutic dose and serum levels of risperidone and active metabolite in geriatric patients. Pharmacotherapy 1995;15:382-3.
13. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
14. Ereshefsky L. Pharmacokinetics and drug interactions: Update for new antipsychotics. J Clin Psychiatr 1996;57:12-25.
15. Carter CS, Mulsant BH, Sweet RA, et al. Risperidone use in a teaching hospital during its first year after market approval: Economic and clinical implications. Psychopharmacol Bull 1995;31: 719-25.
16. Mesotten F, Suy E, Pietquin M, et al. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology 1989;99:445-9.
17. Woestenborghs R, Lorreyne W, Van Rompaey F, et al. Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography. J Chromatogr 1992;583:223-30.
18. Le Moing JP, Edouard S, Levron JC. Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1993;614:333-9.
19. Price MC, Huffman DW. Therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone in serum with solid-phase extraction and high-performance liquid chromatography. Ther Drug Monit 1997;19:333-7.
20. Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 1990;19:241-55.
21. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Potential of concentration monitoring data for a short half-life drug: Analysis of pharmacokinetic variability for moclobemide. Ther Drug Monit 1995; 17:39-46.
22. Jerling M, Merlé Y, Mentré F, et al. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6: An evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1994;38:453-62.
23. Jerling M, Bertilsson L, Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: An example with amitriptyline and nortriptyline. Ther Drug Monit 1994;16:1-12.
24. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: Evaluation of a paired approach for psychotropic medication. Ther Drug Monit 1997;19:1-10.
25. Ereshefsky L, Tran-Johnson T, Davis CM, et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: Evaluation of doxepin and imipramine - New data and review. Clin Chem 1988;34:863-80.
26. Darby JK, Pasta DJ, Elfand L, et al. Risperidone dose and blood level variability: Accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1997;17:478-84.
27. Yonkers KA, Kando JC, Cole JO, et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992;149:587-95.
28. Glue P, Banfield C. Psychiatry, psychopharmacology and P-450s. Hum Psychopharmacol 1996;11:97-114.
29. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
30. Blacker CVR, Mortimore C. Randomized controlled trials and naturalistic data: Time for a change? Hum Psychopharmacol 1996; 11:353-63.
31. Linden M. Phase IV research and drug utilization observation studies. Pharmacopsychiatry 1997;30:1-3.